Ulcerative Colitis News and Research RSS Feed - Ulcerative Colitis News and Research

Ulcerative colitis is a common inflammatory disease of the colon characterized by inflammation and ulceration of the large bowel and rectum. The condition impairs the ability of the large bowel to absorb water which results in diarrhea, the main symptom of the condition.

Ulcerative colitis is a relapsing and remitting condition, meaning symptoms can die down for long periods but then flare-up from time to time. These flare-ups can be sudden and severe. During a period of relapse, symptoms may include bloody diarrhea, abdominal pain and a sudden urge to defecate. Other symptoms include wind, loss of appetite, weight loss, fever and fatigue.

Currently, there is no cure for the condition apart from surgery. However, certain treatments such as corticosteroids or immunosuppressants may be used to ease symptoms by reducing inflammation. Surgery for severe ulcerative colitis that does not respond to treatment involves completely removing the large bowel and re-routing the small bowel so that waste can still be expelled. This procedure is called a colectomy.

In the UK, the incidence of ulcerative colitis is around 1 in 500 and the condition is equally common among males and females. Symptoms can develop at any age, but onset usually occurs between 15 and 30 years of age.
Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Mundipharma International Limited’s network of independent associated companies are launching Remsima® (infliximab) this month in Germany, Italy, UK, Netherlands, Belgium and Luxembourg following expiry of the relevant patents and Supplementary Protection Certificates, having secured distribution rights from Celltrion Healthcare Hungary Kft for Remsima in these markets. [More]
Emulsifiers can alter gut microbiota composition to induce intestinal inflammation

Emulsifiers can alter gut microbiota composition to induce intestinal inflammation

Emulsifiers, which are added to most processed foods to aid texture and extend shelf life, can alter the gut microbiota composition and localization to induce intestinal inflammation that promotes the development of inflammatory bowel disease and metabolic syndrome, new research shows. [More]
Scientists find new links between inflammation and tissue regeneration

Scientists find new links between inflammation and tissue regeneration

Almost all injuries, even minor skin scratches, trigger an inflammatory response, which provides protection against invading microbes but also turns on regenerative signals needed for healing and injury repair - a process that is generally understood but remains mysterious in its particulars. [More]
Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Inflectra is licensed for the treatment of inflammatory conditions including rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, adult and paediatric Crohn’s disease, adult and paediatric ulcerative colitis and plaque psoriasis. [More]
Remsima (infliximab) now available in Europe for treatment of autoimmune diseases

Remsima (infliximab) now available in Europe for treatment of autoimmune diseases

Celltrion Healthcare has today announced the launch of Remsima (infliximab) in 12 European markets: Austria, Belgium, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain, Sweden and the UK. [More]
Actavis files ANDA to market Budesonide Extended-release Tablets

Actavis files ANDA to market Budesonide Extended-release Tablets

Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Budesonide Extended-release Tablets, 9 mg. [More]
Shire announces acquisition of Meritage Pharma

Shire announces acquisition of Meritage Pharma

Shire plc and Meritage Pharma, Inc. announced today that Shire has acquired Meritage, a privately-held company, for an upfront fee of $70 million and additional contingent payments based on the achievement of development and regulatory milestones. [More]
Ferring announces European launch of CORTIMENT®MMX® (budesonide) for ulcerative colitis, and new data re-confirms safety and efficacy

Ferring announces European launch of CORTIMENT®MMX® (budesonide) for ulcerative colitis, and new data re-confirms safety and efficacy

Ferring Pharmaceuticals announced today the European launch of CORTIMENT®MMX® (budesonide), the first and only approved oral controlled release budesonide treatment for active mild-to-moderate ulcerative colitis (UC) where mesalazine (5-ASA) treatment is not sufficient. [More]

Clinical data demonstrates safety, efficacy of vedolizumab for treatment of adults with UC and CD

Takeda Pharmaceuticals International GmbH today announced the presentation of data further demonstrating the efficacy and safety of vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD). [More]
Tillotts Pharma announces results of new survey in UC, introduces UCandME toolbox at ECCO 2015

Tillotts Pharma announces results of new survey in UC, introduces UCandME toolbox at ECCO 2015

Tillotts Pharma announced today results from a new European survey that revealed more than 9 out of 10 people with ulcerative colitis (UC) have low to medium adherence to their medication, putting them at five times greater risk of relapse. [More]
InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

Data have been presented today on the use of Hospira’s Inflectra (infliximab), the world’s first approved biosimilar monoclonal antibody (mAb), at the European Crohn’s and Colitis Organisation Inflammatory Bowel Diseases (ECCO-ibd) conference. [More]

Gut microbial metabolite of linoleic acid has suppressive effect on intestinal inflammation

Inflammatory bowel diseases (IBDs), including Crohn disease and ulcerative colitis, are hard to completely cure. Globally, IBDs affect more than 4 million people, today. However, Professor Soichi Tanabe (Graduate School of Biosphere Science, Hiroshima University) and his collaborators have demonstrated that 10-hydroxy-cis-12-octadecenoic acid (HYA), a gut microbial metabolite of linoleic acid, has a suppressive effect on intestinal inflammation. [More]
TNF signaling molecule triggers Crohn's disease, ulcerative colitis

TNF signaling molecule triggers Crohn's disease, ulcerative colitis

Cells lining the intestinal tract form a critical barrier, protecting our bodies from the billions of bacteria living in the gut. Breaches in this barrier are driven largely by a single signaling molecule called tumor necrosis factor (TNF), elevated amounts of which are associated with inflammatory bowel diseases like Crohn's disease and ulcerative colitis. [More]
Bacteria's DNA can pass trait to offspring in a way similar to parents' own DNA

Bacteria's DNA can pass trait to offspring in a way similar to parents' own DNA

It's a firmly established fact straight from Biology 101: Traits such as eye color and height are passed from one generation to the next through the parents' DNA. [More]
Hospira announces launch of first biosimilar monoclonal antibody in Europe

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Hospira, Inc., a world leader in the development of biosimilar therapies, today announced the launch of the first biosimilar monoclonal antibody (mAb), Inflectra (infliximab), in major European markets. [More]
OSU researchers discover impact of antibiotics on microorganisms that live in animal's gut

OSU researchers discover impact of antibiotics on microorganisms that live in animal's gut

Researchers at Oregon State University have discovered that antibiotics have an impact on the microorganisms that live in an animal's gut that's more broad and complex than previously known. [More]
New study shows that chronic narcotic use more prevalent in children with IBD

New study shows that chronic narcotic use more prevalent in children with IBD

Chronic narcotic use is more than twice as prevalent in children with inflammatory bowel disease (IBD), compared with children without this disease, according to a new study1 published in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association. [More]
Ohio State allergy specialists study, learn more about eosinophilic esophagitis

Ohio State allergy specialists study, learn more about eosinophilic esophagitis

Its name is daunting. It's the hottest topic among allergy experts. It's showing up more and doctors don't yet know why. Allergy specialists at The Ohio State University Wexner Medical Center are seeing more people with eosinophilic esophagitis (EoE), an inflammatory response in the esophagus that makes it hard to swallow food. [More]
Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Amgen today announced a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 501 compared with Humira® (adalimumab) in patients with moderate-to-severe rheumatoid arthritis met its primary and key secondary endpoints. [More]
VG Life Sciences issues patent relating to treatment of IBD through CLIP-inducing agent

VG Life Sciences issues patent relating to treatment of IBD through CLIP-inducing agent

VG Life Sciences, (VGLS), a biotechnology company developing therapies for autoimmune and infectious diseases, today announced the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8906846, covering a method of treating inflammatory bowel disease (IBD) through the administration of a CLIP-inducing agent. [More]